The extent to which these outcomes might apply to the administration of recombinant human erythropoietin to patients with cancer, treated with chemotherapy to achieve haemoglobin concentrations less than 13 g/ dl, is unclear because few patients with these characteristics were included in the data reviewed.
Ei ole teada, mil määral võivad need tulemused kehtida rekombinantse inimese erütropoetiini manustamise kohta kemoteraapiat saavatele vähihaigetele, et saavutada hemoglobiinisisaldus alla 13 g/ dl, sest uuritud andmed hõlmasid vaid üksikuid selliste tunnustega patsiente.